Tools
Tools
Elzubeir, Amera, High, Juliet 
ORCID: https://orcid.org/0000-0003-2555-2349, Hammond, Matthew ORCID: https://orcid.org/0000-0002-0739-3412, Shepstone, Lee, Pond, Martin ORCID: https://orcid.org/0000-0003-2725-3430, Walmsley, Martine, Trivedi, Palak, Culver, Emma, Aithal, Guruprasad, Dyson, Jessica, Thorburn, Douglas, Alexandre, Leo and Rushbrook, Simon
(2025)
Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): Protocol for a single-arm, multicentre, pilot study.
BMJ Open Gastroenterology, 12 (1).
pp. 1-13.
ISSN 2054-4774
Preview |
PDF (e001596.full)
- Published Version
Available under License Creative Commons Attribution Non-commercial. Download (1MB) | Preview |
Abstract
Introduction Primary sclerosing cholangitis (PSC) is a rare immune-mediated hepatobiliary disease, characterised by progressive biliary fibrosis, cirrhosis, and end-stage liver disease. As yet, no licensed pharmacological therapy exists. While significant advancements have been made in our understanding of the pathophysiology, the exact aetiology remains poorly defined. Compelling evidence from basic science and translational studies implicates the role of T helper 17 cells (Th17) and the interleukin 17 (IL-17) pro-inflammatory signalling pathway in the pathogenesis of PSC. However, exploration of the safety and efficacy of inhibiting the IL-17 pathway in PSC is lacking. Methods and analysis This is a phase 2a, open-label, multicentre pilot study, testing the safety of brodalumab, a recombinant human monoclonal antibody that binds with high affinity to interleukin-17RA, in adults with PSC. This study will enrol 20 PSC patients across five large National Health Service tertiary centres in the UK. The primary outcome of the study relates to determining the safety and feasibility of administering brodalumab in early, non-cirrhotic PSC patients. Secondary efficacy outcomes include non-invasive assessment of liver fibrosis, changes in alkaline phosphatase values and other liver biochemical readouts, assessment of biliary metrics through quantitative MR cholangiography+, and quality of life evaluation on completion of follow-up (using the 5D-itch tool, the PSC-patient-reported outcome and PSC-specific Chronic Liver Disease Questionnaire). Ethics and dissemination Ethical approval for this study has been obtained from the London Bridge Research Ethics Committee (REC23/LO/0718). Written informed consent will be obtained from all trial participants prior to undertaking any trial-specific examinations or investigations. On completion of the study, results will be submitted for publication in peer-reviewed journals and presented at national and international hepatology meetings. A summary of the findings will also be shared with participants and PSC communities.
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |